Researchers Find Impaired Mitochondrial and Metabolic Function in COVID-19 Patients

New research published ahead of print in the American Journal of Physiology-Cell Physiology explores the role of mitochondrial function and related metabolic changes in the inflammatory response seen in people with COVID-19, the disease caused by the SARS-CoV-2 virus.

Dysfunction of mitochondria, the “energy centers” of the cells, may lead to the production of inflammatory cytokines, which alters immune response. Cytokines are proteins involved in cell signaling. Severe cases of COVID-19 may cause a heightened immune response called a “cytokine storm,” in which the immune system attacks the body. Researchers analyzed changes in the mitochondria of peripheral blood mononuclear cells—highly specialized immune cells—in people diagnosed with COVID-19. They found impaired mitochondrial function, particularly in the process of breaking down glucose (glycolysis).

“In summary, our study identifies the important metabolic alteration in live cells from COVID-19 patients. It paves the way to investigate whether restoring mitochondrial function and/or targeting glycolysis with new or existing drugs can potentially be used for treatment for COVID-19 patients,” the authors wrote.

Read the full article, “Mitochondrial metabolic manipulation by SARS-CoV-2 in peripheral blood mononuclear cells of COVID-19 patients.” Contact the APS Communications Office to schedule an interview with the research team.